DPYD and fatty liver disease: Since the DPYD inhibitor, Gimeracil, is already deemed safe and tolerable in the clinic when delivered in combination with the chemotherapeutic 5-FU for the treatment of various cancers, Gimeracil may be a promising therapeutic for the alleviation of hepatic steatosis.